ABCD1 and X-linked adrenoleukodystrophy: However, so far, only lentivector-mediated gene replacement approach administered intracerebrally to ALD patients is being tested in a Shenzhen Geno-Immune Medical Institute-sponsored phase 1/2 clinical trial using a self-inactivating LV (TYF-ABCD1; NCT03727555).